↓ Skip to main content

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

Overview of attention for article published in Cancer Immunology, Immunotherapy, July 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#43 of 1,840)
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
8 tweeters
patent
2 patents
facebook
3 Facebook pages

Citations

dimensions_citation
188 Dimensions

Readers on

mendeley
160 Mendeley
Title
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
Published in
Cancer Immunology, Immunotherapy, July 2012
DOI 10.1007/s00262-012-1319-0
Pubmed ID
Authors

Surasak Phuphanich, Christopher J. Wheeler, Jeremy D. Rudnick, Mia Mazer, HongQian Wang, Miriam A. Nuño, Jaime E. Richardson, Xuemo Fan, Jianfei Ji, Ray M. Chu, James G. Bender, Elma S. Hawkins, Chirag G. Patil, Keith L. Black, John S. Yu

Abstract

This study evaluated the safety and immune responses to an autologous dendritic cell vaccine pulsed with class I peptides from tumor-associated antigens (TAA) expressed on gliomas and overexpressed in their cancer stem cell population (ICT-107).

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 160 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 5 3%
Netherlands 2 1%
Switzerland 2 1%
Germany 1 <1%
Brazil 1 <1%
India 1 <1%
Spain 1 <1%
Unknown 147 92%

Demographic breakdown

Readers by professional status Count As %
Researcher 41 26%
Student > Ph. D. Student 38 24%
Student > Bachelor 22 14%
Student > Master 14 9%
Other 13 8%
Other 32 20%
Readers by discipline Count As %
Medicine and Dentistry 60 38%
Agricultural and Biological Sciences 48 30%
Biochemistry, Genetics and Molecular Biology 15 9%
Immunology and Microbiology 13 8%
Neuroscience 6 4%
Other 18 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2016.
All research outputs
#1,310,533
of 12,772,009 outputs
Outputs from Cancer Immunology, Immunotherapy
#43
of 1,840 outputs
Outputs of similar age
#12,694
of 120,937 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#4
of 27 outputs
Altmetric has tracked 12,772,009 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,840 research outputs from this source. They receive a mean Attention Score of 4.6. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 120,937 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.